Exodus Point Capital Management, LP Castle Biosciences Inc Transaction History
Exodus Point Capital Management, LP
- $14.6 Billion
- Q4 2024
A detailed history of Exodus Point Capital Management, LP transactions in Castle Biosciences Inc stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 11,484 shares of CSTL stock, worth $317,073. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,484
Previous 44,263
74.06%
Holding current value
$317,073
Previous $1.26 Million
75.75%
% of portfolio
0.0%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding CSTL
# of Institutions
209Shares Held
26.7MCall Options Held
278KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$84.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$50.6 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.8MShares$49.6 Million0.24% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.44MShares$39.6 Million0.02% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$34.8 Million0.61% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $726M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...